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 Abstract 
 
Background: Inhibitors are antibodies that neutralize coagulation factors. They are 
immunoglobulin’s, arising in congenitally deficient individuals as a result of 
administration of missing factors. The development of inhibitors remains one of the 
most serious complications of replacement therapy in haemophilia A patients. 
Inhibitors makes control of bleeding difficult as they need higher doses of factors or 
bypassing agents, these are coasty and are not always available. This problem is under 
estimated and needs further work up to detect the true incidence and the risk factors 
and their effect on management.  
Objectives: To determine the prevalence of inhibitors in patients with haemophilia 
A and correlate the severity of illness with inhibitors level by measuring  FVIII level 
and FVIII inhibitors.  
Design: Cross sectional prospective study                                                                                    
 Setting:  Haemophilia clinic in Khartoum Teaching Hospital in the period from 
January to May 2010. 
Methods: Eighty patients with haemophilia A were included in the study .All 
patients were males with different disease severities (mild, moderate and severe). 
Their ages ranged from 3-60 years. Samples were collected from patients for Factor 
VIII level and inhibitor quantification.  Inhibitor quantification was done by Bethesda 
assay and expressed in Bethesda unit (BU). 
 Results: Seventeen patients (21.3%) were found to have inhibitors, fifteen patients 
with low titre inhibitors (18.8%) and two of high titre (2.5%). Those with high titre 
inhibitors had more frequent visits to haemophilia clinic and received more units of 
factor VIII during the last month.  
No correlation was found between the severity of the disease and the number of visits 
during the last year. Inhibitors are most common among severely diseased patients but 
the correlation between the severity of the disease and the inhibitors was not 
significant for those with mild and moderate disease. 
Conclusion: The prevalence of factor VIII inhibitors in this group of patients with 
haemophilia A was 21.3% (seventeen patients). Fifteen patients of low titre inhibitors 
(18.8%) and two of high titre (2.5%).This result was significant as the prevalence of 
inhibitors was 15-25% in haemophilia A as mentioned in the literature . Inhibitors are 
most common among severely diseased patients. Those with inhibitors had more 
frequent visits and receive more amount of factor VIII concentrate during the last 
month when compared with patients with no inhibitors . 
 
 
 
 
 
 
 
 
  اﻟﻤﺴﺘﺨﻠﺺ
  
 ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺃﺠﺭﻴﺕ ﻟﻤﻌﺭﻓﺔ ﻨﺴﺒﺔ ﺍﻻﺠﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﺓ ﻟﺩﻯ ﻤﺭﻀﻰ ﺍﻟﻬﻴﻤﻭﻓﻴﻠﻴﺎ :ﻤﻘﺩﻤﺔﺍﻟ
ﺘﻌﺘﺒﺭ ﺍﻻﺠﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﺓ ﻤﻥ .( ﻤﻥ ﻨﻘﺹ ﺍﻟﻌﺎﻤل ﺍﻟﺜﺎﻤﻥ ﻟﻠﺘﺠﻠﻁ ﺴﻴﻭﻟﺔ ﺍﻟﺩﻡ ﺍﻟﻨﺎﺘﺠﺔ)( ﺃ)
ﺍﻟﻤﺸﺎﻜل ﺍﻟﺨﻁﺭﺓ ﺍﻟﺘﻰ ﻴﺘﻌﺭﺽ ﻟﻬﺎ ﻤﺭﻴﺽ ﺍﻟﻬﻤﻭﻓﻴﻠﻴﺎ ﺤﻴﺙ ﺘﺘﺴﺒﺏ ﻓﻰ ﻋﺩﻡ ﺍﺴﺘﺠﺎﺒﺔ 
ﺍﻟﻤﺭﻴﺽ ﻟﻠﻌﻼﺝ ﻭﻴﺤﺘﺎﺝ ﺍﻟﻤﺭﻴﺽ ﻟﺠﺭﻋﺎﺕ ﻤﻀﺎﻋﻔﺔ ﻤﻥ ﺍﻟﻌﺎﻤل ﺍﻟﺜﺎﻤﻥ ﺃﻭ ﻋﻼﺠﺎﺕ 
ﺍﻟﺴﻭﺩﺍﻥ ﻭﺘﺤﺘﺎﺝ  ﺍﻟﻤﺸﻜﻠﺔ ﻟﻡ ﻴﺘﻡ ﺒﺤﺜﻬﺎ ﻓﻲ ﻫﺫﻩ .ﺍﺨﺭﻯ ﻏﻴﺭ ﻤﺘﻭﻓﺭﺓ ﻓﻰ ﺃﻏﻠﺏ ﺍﻻﺤﻴﺎﻥ
  .ﻟﻤﺯﻴﺩ ﻤﻥ ﺍﻟﺩﺭﺍﺴﺎﺕ ﻟﺘﻘﻴﻴﻤﻬﺎ ﻭﻤﻌﺭﻓﺔ ﺍﺜﺎﺭﻫﺎ ﻋﻠﻰ ﺍﻟﻤﺭﻀﻰ ﻭﻋﻼﺠﻬﻡ
ﻗﻴﺎﺱ ﻨﺴﺒﺔ ﺍﻟﻌﺎﻤل ﺍﻟﺜﺎﻤﻥ ﻟﻤﺭﻀﻰ ﺍﻟﻬﻴﻤﻭﻓﻴﻠﻴﺎ، ﻗﻴﺎﺱ ﻨﺴﺒﺔ ﺍﻻﺠﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﺓ :  ﺍﻻﻫﺩﺍﻑ
ﻭﻤﻘﺎﺭﻨﺔ ﻨﺴﺒﺔ ﺍﻻﺠﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﺓ ﻤﻊ ( ﺍﻟﻌﺎﻤل ﺍﻟﺜﺎﻤﻥ) ﺍﻟﻤﺘﻜﻭﻨﺔ ﻟﺩﻴﻬﻡ ﺒﻌﺩ ﺘﻌﺎﻁﻰ ﺍﻟﻌﻼﺝ
  .ﺤﺩﺓ ﺍﻟﻤﺭﺽ
  .ﻭﺼﻔﻴﺔ ﻤﻘﻁﻌﻴﺔ ﺩﺭﺍﺴﺔ :ﺴﺔﻨﻭﻉ ﺍﻟﺩﺭﺍ
ﻤﺴﺘﺸﻔﻰ ﺍﻟﺨﺭﻁﻭﻡ ﺍﻟﺘﻌﻠﻴﻤﻰ ﺒﻌﻴﺎﺩﺓ ﺍﻟﻬﻴﻤﻭﻓﻴﻠﻴﺎ ﻓﻰ ﺍﻟﻔﺘﺭﺓ ﻤﻥ ﻴﻨﺎﻴﺭ ﺍﻟﻰ  :ﻤﻜﺎﻥ ﺍﻟﺩﺭﺍﺴﺔ
 .ﻋﺸﺭ ﻭﺃﻟﻔﻴﻥ ﻤﺎﻴﻭ ﺴﻨﺔ
ﻋﻤﺎﺭﻫﻡ ﻤﻥ ﺘﻀﻤﻨﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺜﻤﺎﻨﻴﻥ ﻤﺭﻴﻀﺎ  ﻜﻠﻬﻡ ﻤﻥ ﺍﻟﺫﻜﻭﺭ ﺘﺘﺭﺍﻭﺡ ﺃ :ﺍﻟﺒﺤﺙ ﻤﻨﻬﺞ
ﺃﺨﺫﺕ . ﻤﺘﻭﺴﻁ ﺃ ﻭ ﺤﺎﺩ, ﺴﻨﺔ ﻜﻤﺎ ﺘﺘﺭﺍﻭﺡ ﺤﺩﺓ ﺍﻟﻤﺭﺽ ﻟﺩﻴﻬﻡ ﻤﻥ ﺨﻔﻴﻑ  ﻥﺜﻼﺙ ﺍﻟﻰ ﺴﺘﻴ
ﻨﺴﺒﺔ ﺍﻟﻌﺎﻤل ﺍﻟﺜﺎﻤﻥ ﻭﻨﺴﺒﺔ ﻋﻴﻨﺎﺕ ﻤﻥ ﺍﻟﺩﻡ ﻭﺍﺠﺭﻴﺕ ﻓﻴﻬﺎ ﺍﻟﻔﺤﻭﺼﺎﺕ ﺍﻟﻼﺯﻤﺔ ﻟﻤﻌﺭﻓﺔ 
  .ﺍﻻﺠﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﺓ
 ﺨﻤﺴﺔ ﻋﺸﺭ  %.1.12ﺴﺒﻌﺔ ﻋﺸﺭ ﻤﺭﻴﺽ ﻭﺠﺩﺕ ﻟﺩﻴﻬﻡ ﺃﺠﺴﺎﻡ ﻤﻀﺎﺩﺓ ﺒﻨﺴﺒﺔ  :ﺍﻟﻨﺘﺎﺌﺞ
ﺒﻴﻨﻤﺎ ﺍﺜﻨﺎﻥ ﻟﺩﻴﻬﻡ ﻨﺴﺒﺔ ﻋﺎﻟﻴﻪ ﻤﻥ % 8.81ﻬﻡ ﻗﻠﻴل ﻤﻨﻬﻡ ﻜﺎﻥ ﻤﺴﺘﻭﻯ ﺍﻻﺠﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﻩ ﻟﺩﻴ
ﻭﻯ ﺍﻟﻤﺭﺽ ﺫﺘﺭﺘﻔﻊ ﻨﺴﺒﺔ ﺍﻻﺠﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﺓ ﻟﺩﻯ ﺍﻟﻤﺭﻀﻰ %.5.2.ﺓﺍﻻﺠﺴﺎﻡ ﺍﻟﻤﻀﺎﺩ
ﻭﻯ ﺍﻟﻤﺭﺽ ﺫﺍﻟﺤﺎﺩ ﺒﻴﻨﻤﺎ ﻟﻡ ﺘﺜﺒﺕ ﺍﻟﻌﻼﻗﺔ ﺒﻴﻥ ﺘﻜﻭﻥ ﺍﻻﺠﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﺓ ﻭﺤﺩﺓ ﺍﻟﻤﺭﺽ ﻟﺩﻯ 
ﺍﻟﻤﻀﺎﺩﺓ ﻴﺘﺭﺩﺩﻭﻥ ﺍﻟﻤﺭﻀﻰ ﺍﻟﺫﻴﻥ ﻟﺩﻴﻬﻡ ﻨﺴﺒﺔ ﻋﺎﻟﻴﺔ ﻤﻥ ﺍﻻﺠﺴﺎﻡ . ﺍﻟﺨﻔﻴﻑ ﻭﺍﻟﻤﺘﻭﺴﻁ
    .ﺨﺭﻴﻥﺒﺎﺴﺘﻤﺭﺍﺭ ﻟﺘﻠﻘﻰ ﺍﻟﻌﻼﺝ ﻭﻴﺤﺘﺎﺠﻭﻥ ﻟﻜﻤﻴﺎﺕ ﻜﺒﻴﺭﺓ ﻤﻨﻪ ﻤﻘﺎﺭﻨﺔ ﺒﺎﻵ
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1 
Introduction and literature review 
 
Normal haemostasis: 
 
Haemostasisis a number of protective processes that have evolved in order to 
maintain a stable physiology. Haemostasis refer to the process whereby blood 
coagulation, initiated and terminated in a tightly regulated fashion, together with 
the removal of the clot (fibrinolysis) as a part of vascular remodeling. As such 
haemostasis describes the global process by which vessel integrity and patency 
are maintained over the whole organism for its lifetime. Haemostatic 
mechanisms are integrated so that thrombin generation is localized, limited and 
followed by fibrinolysis and tissue remodeling, which are also localized and 
limited(1). 
Normal haemostasis involves five major components, platelets, coagulation 
factors, coagulation inhibitors, fibrinolysis and blood vessels. Following blood 
vessel injury two processes are activated. 
? Platelet adhesion to areas of vascular injury with the subsequentformation 
of a platelet thrombus. 
? Surface or tissue contact mediated activation of coagulation with 
Sequential enzymic reactions culminating in the formation of a fibrin 
thrombus(2). These two processes are interactive, although their dominance 
varies in different sites of the vascular system. Activation of haemostasis is 
accompanied by activation of the fibrinolytic system which should eventually 
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achieve partial or complete removal of the thrombus(3). Blood coagulation 
occurs when the enzyme thrombin is generated and proteolyses soluble plasma 
fibrinogen forming insoluble fibrin polymers or clot. Thrombin generation is a 
complex net work of interactions with positive and negative feedback loops. 
Tissue factor (TF) initiates blood coagulation, it is expressed at biological 
boundaries such as the skin, organ surfaces, vascular adventitia and epithelial 
mesenchymal surfaces where it function as haemostatic envelope. This ensures 
that following disruption of vascular integrity blood is immediately exposed to 
cells expressing TF, leading to the initiation of blood coagulation. Exposure of 
the circulating zymogene FVII to membrane bound TF lead to activation of 
FVII to FVIIa and formation of a very high affinity complex of TF with FVIIa 
result in activation of FIX and FX. In the absence of its activated cofactor FVa, 
FXa generate small trace amount of thrombin from prothrombin although 
insufficient to initiate significant fibrin polymerization,thrombin formed in this 
initiation stage of coagulation is able to back activate FV and FVIII by limited 
proteolysis.(1) 
In the amplification phase of coagulation ,FVIIIa forms a complex with FIXa , 
the FX- ase complex ( FVIIIa – FIXa ) and activate sufficient FXa that in 
complex with FVa form prothrombinase complex ( FVa – Fxa ) resulting in 
explosive generation of thrombin that ultimately leads to generation of a fibrin 
clot. 
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A key feature of these processes is the assembly of multiprotein complexes on 
phospholipid surface provided by cell surfaces, for procoagulant complexes 
such as FX-ase and prothrombinase, this surface is provided by activated 
platelets 
The coagulation factors are either enzymes precursors or cofactors. All the 
enzymes except FXIII are serine proteases .i.e. their ability to hydrolyse peptide 
bonds depends upon the amino acid serine at their active site. The scale of 
amplification achieved in this system is dramatic e.g. 1mol of activated FXI 
through sequential activation of FIX, X and prothrombin may generate up to2x 
( mol of fibrin.  
Feedback inhibition of coagulation occurs by: 
• Tissue factor pathway inhibitor (TFPI) 
• Anti thrombin (AT) which form inactive complex as with FIX, FX, FXI and 
thrombin. 
• Thrombin also proteolyticaly activate an anti coagulation pathway (protein C 
pathway), Thrombomodulin (TM) an endothelial cell surface receptor plays 
a role in activation of this pathway. In complex with its cofactor ,protein 
S(ps),APC rapidly inactivates the procoagulant cofactors FVa and FVIIIa by 
specific proteolysis(1).   
•  Heparin potentiates the action of anti thrombin. 
• Heparin cofactor 2 also inhibits thrombin. 
• α2 macroglobulin, α 1 anti trypsin, α2 anti plasmin and C1 esterase 
inhibitor(3). 
Fibrionolysis occurs by fibrinolytic system.Components of the fibrinlytic 
system include plasminogen and plasmin, several endogenous (tissue or plasma 
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derived)or exogenous(bacterial or venom derived) plasminogen activators and 
inhibitors. Generation of fibrin and its binding of tissue plasminogen activators 
(TPA) lead to increase in the affinity of TPA for plasminogen that result in 
generation of plasmin at the site of fibrin clot .Plasmin can hydrolyse a variety 
of substrates including factors V and VIII ,but its major physiological targets 
are fibrin and fibrinogen ,which are split progressively  leading to generation of 
fibrin   degradation products (FDPs) .Fibrinolytic system is inhibited by 
plasminogen activator inhibitor , (PAT_I) and α2 antiplasmin(1). 
In the classical pathway formulated toexplain in vitro coagulation testing, 
initiation of the pathway requires contact reaction between FXII, kallikren and 
high molecular weight kininogen (MWK) leading to activation of FXI. 
However, Lack of abnormal bleeding in individuals with hereditary deficiencies 
of these factors suggests that these reactions are not required for physiological 
coagulation in vivo. FXI does not seem to have a role in the physiological 
initiation of coagulation; it has a supplementary role in the activation of FIX 
and may be important at major sites of trauma or for operation(3).  
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Haemophilia A (classic haemophilia) 
Definition: 
Haemophilia A is an x-linked hereditary disorder that is due to defective or 
deficient factor VIII molecule. The estimated incidence is only 1in every 10000 
live male birth. It’s found in all ethnic groups in all parts of the world(4) 
Etiology and pathogenesis: 
Haemophilia A is a heterogeneous disorder resulting from defects in the factor 
VIII gene that leads to a reduction in the circulating level of functional 
FVIII.The reduction in the activity can be due to a decreased amount of FVIII 
protein, the presence of functionally abnormal protein or both (5). Coagulation 
FVIII is a single chain protein with 350,000 Mw coded by 186kb gene located 
in the Long arm of the X chromosome. FVIII is bound in plasma to VWF. It is 
synthesized in the liver by hepatocytes. For FVIII to be an effective cofactor for 
FIX it must be activated by thrombin, a reaction that results in the formation of 
a heterotrimer composed of A1, A2, and A3-C1-C2 domains of FVIII in a 
complex with calcium (6).Activated FVIII and activated FIX associate on the 
surface of activated platelets to form a functional FX –activating 
complex(tenase or x-ase).It is not surprising that haemophilia  A and B have 
similar clinical presentation ,since both FVIII and IX are required to form x-ase 
complex. In patient with haemophilia, clot formation is delayed because 
thrombin generation is markedly decreased; the clot that is formed is friable and 
easily dislodged leading to excessive bleeding.(7) 
Genetics: 
Haemophilia A is an x-linked recessive disorder that occurs in males and 
homozygous females; however mild haemophilia has been described in 
heterozygous females presumably due to extremely unfavorable lionization 
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(inactivation of normal x chromosome in most of the cells). Approximately 30% 
of patients of haemophilia have no family history; their disease presumably can 
be due to new mutations. 
Factor VIII gene is very large, about 186kb with about 9kb of exons,it contain 
26 exons and 25 intervening sequences or introns. Specific mutations and 
alterations that results in haemophilia eg: gene rearrangement, missense 
mutations (in which there is a single base substitution leading to an amino acid 
change), nonsense mutations (which result in stop codon), abnormal splicing of 
the gene, deletion of all or portions of the gene or insertion of genetic 
elements(8). 
One of the most common mutations, accounting for40-50% of patients is a 
unique combined gene inversion and crossing over that disrupt FVIII gene, 
many of these patients are susceptible to develop FVIII inhibitors. 
Large deletions in FVIII gene are always associated with severe haemophilia 
and some develop inhibitors(9). 
 
Clinical feature:  
Hemophilia is characterized by excessive bleeding into various parts of the 
body. Soft tissue hematomas and hemoarthroses leading to severe crippling 
hemarthropathy are highly characteristic of the disease. The disease is classified 
as: 
• Mild: if the factor level 5 – 30% of normal (0.05 – 0.30 u/ml) those develop 
hemorrhage secondary to trauma or surgery they rarely develop spontaneous 
bleeding. 
• Moderate: 1 – 5% of normal (0.01 – 0.05 u/ml) those also develop 
hemorrhage secondary to trauma or surgery but they have occasional 
spontaneous hemorrhage. 
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• Severe: ≤ 1% of normal (≤ 0.01u/ml) those have spontaneous hemorrhage 
from early infancy and frequent hemarthrosis(10). 
So the severity and frequency of bleeding are inversely correlated with the 
residual FVIII level. The most affected area is the strain bearing joints e.g. 
knees, ankles and elbows, if untreated this intra capsular bleeding causes 
swelling, pain, stiffness and inflammation. It’s not clear why bleeding in 
hemophilia shows predilection for joints (Tissue factor pathway inhibitor in 
synovial tissue may be part of the explanation) (TFPI). Muscle bleeding most 
often affect large load bearing groups of muscles of the thigh, calf, posterior 
abdominal wall and buttocks, but can occur anywhere. Local pressure effect 
can cause entrapment neuropathy particularly of femoral nerve with 
illiopsoas bleeding(1). 
? Hematuria is less common and it can cause clot colic. 
? CNS bleeding is un common but can occur after slight head injury and it’s 
a common cause of death. 
? GIT bleeding and oropharyngeal bleeding are uncommon. 
? Bruising is a feature of haemophilia (A) but it’s usually self limiting. 
? Pseudo tumors (blood cysts) are blood cysts that occurs is soft tissues or 
bones. They are rare but dangerous complication of haemophilia. 
? Mucous membrane hemorrhage is common in haemophilia (epistaxis and 
hemoptysis).  
? Surgery and open trauma invariably lead to dangerous hemorrhage. 
 
So presentation of haemophilia: 
• In neonates: cephalohematoma, prolonged bleeding from umbilical cord and 
post circumcision. 
• In childhood: joint bleeding, bleeding from eruption of primary dentitions 
and post trauma. 
• Mild case may present in late life with severe trauma or surgery (1). 
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Laboratory features: 
Patients with severe hemophilia A characteristically have prolonged APTT 
(activated partial thromboplastin time. the PT, BT and thrombin clotting time 
(TCT) are normal although minor increase in BT have been reported by some 
investigators(11). 
The APTT is corrected when haemophilic plasma is mixed with an equal 
volume of normal plasma. If the haemophilic plasma contains an inhibitor 
(antibodies against FVIII) the APTT on a similar mixture will be prolonged, 
although incubation of the mixture for 1 – 2 h at 37  may be required to detect 
the prolongation. 
A definitive diagnosis of hemophilia A is based on a specific assay for FVIII 
activity. Functional FVIII coagulant activity is measured by one stage clotting 
assay based on APTT. Chromo metric assay are used for factor VIII activity. 
FVIII antigen is measured by immunologic assays which will defect normal and 
most abnormal FVIII molecules, if the FVIII antigen level is normal but the 
clotting activity is reduced, the patient has a dysfunctional FVIII molecule, such 
patients have antigen –positive haemophilia and also referred to as cross 
reacting material –positive (CRM+).In other patients both FVIII antigen and 
activity are nearly undetectable – these Patients are CRM negative. 
FVIII activity is expressed as percent of normal or as unit per milliliter of 
plasma. By definition 1 unit of FVIII is equal to the amount in 1 ml of pooled 
fresh normal human plasma. Also by definition 1 unit of FVIII/ml is 100% of 
normal(11). 
Prenatal diagnosis and carrier detection: 
A careful and complete family history is important for carrier detection. All the 
daughters of haemophilic father will be obligatory carriers of the hemophilic 
defect. Carrier detection becomes important when daughter of a known carrier 
or a female offspring of a patient with hemophilia wishes to become pregnant. 
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If resources for advanced carrier detection are not available one can take a 
careful history and measure both FVIII and VWF The ratio of VWF to FVIII is 
higher in carriers(12). 
Therapy: 
General: general principle includes: 
? Avoidance of trauma. 
? Avoidance of aspirin, non steroidal anti inflammatory drugs and other agents 
that interfere with platelets aggregation. 
? Avoid (im) injections. 
Hemorrhagic episodes can be managed by replacing FVIII;several plasma 
products can be used (13).  
? Fresh frozen plasma: contain FVIII but the disadvantage is that large 
volume must be infused to achieve and maintain FVIII level. 
? Cryo precipitate can be used to attain normal level of FVIII. 
? Several commercial lyophilized FVIII concentrate, now available. FVIII 
concentrate have been sterilized either by heating in solution, super 
heating to 80 after lyophilization or by exposure to organic solvents 
(detergent that inactivate enveloped viruses including HIV,HBV and 
HCV). 
? Plasma derived FVIII concentrate prepared by monoclonal antibody 
techniques and subjected to one of the procedures mentioned above are 
highly purified. 
? FVIII produced by recombinant DNA techniques is now available and 
both safe and effective. 
? Porcine FVIII is also used and it is useful in patient with FVIIII 
antibodies, because the antibodies maynot cross- react with porcine 
FVIII. 
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? DDAVP (1,8 desamino –D- arginine vasopressin, desmopresin), causes 
atransient rise in  FVIII in normal subjects and those with mild to 
moderate haemophilia but not in patients  with severe haemophilia. The 
peak response to DDAVP usually occurs 30 – 60 min post infusion, but 
some patients will not respond. 
? Antifibrinolytic agents: e.g. episilon- amino coproic acid (EACA) and 
tranexamic acid have been used to enhance haemeostasis in patients with 
hemophilia A. They may be given as adjunctive therapy for bleeding 
from mucous membranes and dental procedures. The usual dose for adult 
is 1g four times daily. 
? Fibrin glue:  fibrin tissue adhesives, it contain fibrinogen, thrombin, and 
FVIII. It’s placed on the site of injury and clotted with thrombin solution 
containing calcium; as a result the fibrin clot is cross-linked and anchored 
to tissue. 
? Liver transplantation: have been successfully transplanted into patients 
with haemophilia with resulting cure of hemophilic condition, but it’s 
rare because donors of livers are not available. 
? Gene replacement therapy may offer ideal prophylactic treatment for 
hemophilia A. Haemophilia is an excellent model for gene therapy, 
because the clinical manifestation is the result of deficiency of a single 
gene product and only small amount of the product (protein) is required 
to ameliorate symptoms. 
 
 
Course and prognosis:  
The use of replacement therapy has not been without significant complications. 
The development of antibodies (inhibitors, circulating anticoagulants) against 
FVIII is one of the serious complications. 
11 
Liver disease resulting from viral hepatitis B&C and HIV, Aids is now leading 
cause of death in older patients with hemophilia(14). 
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Haemophilia B 
Haemophilia B is a blood clotting disorder caused by a mutation of the Factor 
IXgene, leading to a deficiency of Factor IX. It is the least common form of 
haemophilia, rarer than haemophilia A. It is sometimes called Christmas disease 
after Stephen Christmas, the first patient described with this disease.The factor 
IX gene is located on the X chromosome (Xq27.1-q27.2). It is an X-linked 
recessive trait, which explains why, as in haemophilia A, only males are usually 
affected. 1 in 50,000 males are affected. 
Factor IX deficiency leads to an increased propensity for haemorrhage. This is 
in response to mild trauma or even spontaneously, such as in joints 
(haemarthrosis) or muscles. The symptoms experienced by those affected are 
similar to those with Haemophilia A. 
The level of Factor IX in the blood determines the severity of Haemophilia B. 
Factor Levels of less than 1-2% is found in people with severe haemophilia and 
they experience spontaneous bleeds into joints or muscles. 
Moderate haemophilia is found in people with factor levels of 2-5%, they may 
experience spontaneous bleeds into joints and muscles. Or those with mild 
haemophilia, who have factor levels of between 5-50%, usually only experience 
Bleeds flowing trauma or surgery. 
The major problem in severe Haemophilia B is painful bleeding into joints, 
mainly the knees, ankles and elbows. These bleeds may occur spontaneously. If 
left not treated promptly the bleeds may result in permanent arthritis and 
disability. Most children and adolescents with severe Haemophilia B receive 
preventative treatment (prophylaxis) with an intravenous infusion of Factor IX, 
2 times a week. This is to prevent spontaneous joint and muscle bleeds. 
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Factor IX has a longer half life than factor VIII and as such factor IX can be 
transfused less frequently. 
With appropriate management and factor replacement children and adults with 
inherited bleeding disorders can live active and normal lives(15). 
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Von Willebrand Disease 
Background: 
Although referred to as a single disease, von Willebrand disease (VWD) is in 
fact a family of bleeding disorders caused by an abnormality of the von 
Willebrand factor (VWF). vonWillebrand disease is the most common 
hereditary bleeding disorder. First described by Erik Adolf von Willebrand in 
1926, von Willebrand disease is a congenital bleeding disorder characterized by 
a lifelong tendency toward easy bruising, frequent epistaxis, and 
menorrhagia(16). 
Pathophysiology 
Von Willebrand disease is due to an abnormality, either quantitative or 
qualitative, of the von Willebrand factor, which is a large multimeric 
glycoprotein that functions as the carrier protein for factor VIII (FVIII). Von 
Willebrand factor is also required for normal platelet adhesion. As such, von 
Willebrand factor functions in both primary (involving platelet adhesion) and 
secondary (involving FVIII) hemostasis. In primary hemostasis, von Willebrand 
factor attaches to platelets by its specific receptor to glycoprotein Ib on the 
platelet surface and acts as an adhesive bridge between the platelets and 
damaged subendothelium at the site of vascular injury. In secondary hemostasis, 
von Willebrand factor protects FVIII from degradation and delivers it to the site 
of injury.  
Von Willebrand factor is composed of dimeric subunits that are linked by 
disulfide bonds to form complex multimers of low, intermediate, and high 
molecular weights. The small multimers function mainly as carriers for 
FVIII.High–molecular weight multimers have higher numbers of platelet-
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binding sites and greater adhesive properties. Each multimeric subunit has 
binding sites for the receptor glycoprotein Ib on non-activated platelets and the 
receptor glycoprotein IIb/IIIa on activated platelets. This facilitates platelet 
adhesion and platelet aggregation, making high molecular weight multimers 
most important for normal platelet function(16). 
Von Willebrand disease types: 
VonWillebrand disease can be classified into 3 main types. 
• Type 1 von Willebrand disease, which accounts for 70-80% of cases, is 
characterized by a partial quantitative decrease of qualitatively normal von 
Willebrand factor and FVIII. An individual with type 1 von Willebrand 
disease generally has mild clinical symptoms, and this type is usually 
inherited as an autosomal dominant trait; however, penetrance may widely 
vary in a single family. In addition, clinical and laboratory findings may vary 
in the same patient on different occasions. Typically, a proportional 
reduction in von Willebrand factor activity, von Willebrand factor antigen, 
and FVIII is observed in type 1 von Willebrand disease.  
• Type 2 disease accounts for 15-20% of von Willebrand disease cases. Type 2 
von Willebrand disease is a variant of the disease with primarily qualitative 
defects of von Willebrand factor. Type 2 von Willebrand disease can be 
either autosomal dominant or autosomal recessive. Of the 4 described type 2 
von Willebrand disease subtypes (ie, 2A, 2B, 2M, 2N), type 2A von 
Willebrand disease is by far the most common.  
? Type 2A von Willebrand disease is inherited as an autosomal dominant 
trait and is characterized by normal-to-reduced plasma levels of factor 
VIIIc (FVIIIc) and von Willebrand factor. Analysis of von Willebrand 
factor multimers reveals a relative reduction in intermediate and high 
molecular weight multimer complexes. The multimeric abnormalities 
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are commonly the result of in vivo proteolytic degradation of the von 
Willebrand factor. The ristocetin cofactor activity is greatly reduced, and 
the platelet von Willebrand factor reveals multimeric abnormalities 
similar to those found in plasma.  
? Type 2B von Willebrand disease is also an autosomal dominant trait. 
This type is characterized by a reduction in the proportion of high 
molecular weight von Willebrand factor multimers, whereas the 
proportion of low–molecular weight fragments are increased. Patients 
with type 2B von Willebrand disease have a hemostatic defect caused by 
a qualitatively abnormal von Willebrand factor and intermittent 
thrombocytopenia. The abnormal von Willebrand factor has an 
increased affinity for platelet glycoprotein Ib.  
? The platelet count may fall further during pregnancy, in association with 
surgical procedures, or after the administration of desmopressin acetate 
(DDAVP). Although some investigators found DDAVP to be clinically 
useful in persons with type 2B von Willebrand disease , studies directed 
at excluding the 2B variant should be completed before DDAVP is used. 
Measurements of FVIIIc and von Willebrand factor in plasma vary; 
however, studies involving the use of titered doses of ristocetin reveal 
that aggregation of normal platelets is enhanced and induced by 
unusually small amounts of the drug.  
? In patients with the rare type 2M von Willebrand disease, laboratory 
results are similar to those of certain patients with type 2A von 
Willebrand disease. Type 2M von Willebrand disease is characterized 
by a decreased platelet-directed function that is not due to a decrease of 
high–molecular weight multimers. Laboratory findings show decreased 
von Willebrand factor activity, but von Willebrand factor antigen, FVIII, 
and multimer analysis are found to be within reference range.  
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? Type 2N von Willebrand disease is also rare and is characterized by a 
markedly decreased affinity of von Willebrand factor for FVIII, 
resulting in FVIII levels reduced to usually around 5% of the reference 
range. Other von Willebrand factor laboratory parameters (ie, von 
Willebrand factor antigen [VWF:Ag], ristocetin cofactor activity) are 
usually normal. The FVIII-binding defect in these patients is inherited in 
an autosomal recessive manner. Evaluate patients with FVIII deficiency 
and a bleeding disorder that is not clearly transmitted as an X-linked 
disorder or those who respond incompletely to hemophilia A therapy for 
type 2N von Willebrand disease. Unfortunately, the confirmatory test for 
type 2N von Willebrand disease is not routinely available, likely 
resulting in an underestimate of the true frequency of this subtype. 
• Type 3 is the most severe form of von Willebrand disease. In the 
homozygous patient, type 3 von Willebranddisease is characterized by 
marked deficiencies of both von Willebrand factor and FVIIIc in the plasma, 
the absence of von Willebrand factor from both platelets and endothelial 
cells, and a lack of response to DDAVP. Type 3 von Willebrand disease is 
characterized by severe clinical bleeding and is inherited as an autosomal 
recessive trait. Consanguinity is common in kindreds with this variant. Less 
severe clinical abnormalities and laboratory abnormalities may be identified 
in occasional heterozygotes; however, such cases are difficult to identify. 
Multimeric analysis of the small amount of von Willebrand factor present 
yields variable results, in some cases revealing only small multimers(16). 
Mortality/Morbidity 
VonWillebrand disease is estimated to affect about 1% of the population.The 
morbidity in individuals with von Willebrand disease varies. Many children 
with von Willebrand disease are asymptomatic. Some of these children have 
cutaneous and/or mucus membrane bleeding (eg, easy bruising, epistaxis). 
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Menorrhagia is a common symptom in females with von Willebrand disease. It 
occurs in more than 50% of women with von Willebrand disease and may be 
the only clinical manifestation of the disease. The rare type 3 von Will brand 
disease can manifest with severe bleeding symptoms similar to severe 
hemophilia (eg, hemarthrosis, intramuscular bleeding). 
Race: No influence of ethnicity on the prevalence of von Willebrand disease 
has been reported. 
Sex: VonWillebrand disease affects males and females in equal numbers. 
Age: vonWillebrand disease is a congenital bleeding disorder and can be 
diagnosed at any age. 
Clinical: 
• Many children with von Willebrand disease (VWD) are asymptomatic and 
are diagnosed as a result of a positive family history or during routine 
preoperative screening (eg, prolonged bleeding time). Importantly, 
remember that a wide variation in clinical manifestations is observed, even 
for members of the same family.   
• The diagnosis of von Willebrand disease can be challenging and depends on 
an accurate personal and family bleeding history, as well as demonstration of 
a low von Willebrand factor (VWF) level.1 
• The history may reveal the following:  
? Increased or easy bruising  
? Recurrent epistaxis  
? Menorrhagia  
? Postoperative bleeding (particularly after tonsillectomy or dental 
extractions)  
? Family history of a bleeding diathesis  
? Bleeding from wounds  
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? Gingival bleeding  
? Postpartum bleeding 
Causes: 
Von Willebrand disease is caused by an inherited defect that results in a 
deficiency or dysfunction of von Willebrand factor. The gene for von 
Willebrand factor is on the short arm of chromosome 12. It spans approximately 
180 kilobases (kb) and is composed of 52 exons. Exons range in size from 40 
base pairs (bp) to 1.4 kb. Various point mutations, insertions, and deletions at 
the von Willebrand factor locus have been described.  
In some cases, von Willebrand disease is believed to result from other 
pathologic processes; however, because of the relatively high prevalence of von 
Willebranddisease, its concomitant occurrence with other disease states may be 
coincidental(16). 
 
Tests and diagnosis: 
 The diagnostic assessments work-up of VWD can be divided into three steps: 
1. Identification of patients suspected for VWD, on the basis of data from 
personal and family clinical history and results of the screening tests of 
hemostasis.  
2. Diagnosis of VWD with identification of its type. 
3. Characterization of the subtype. 
 
Screening tests: 
These tests are usually applied to patients with suspected bleeding tendency. 
The platelet count isusually normal, but mild thrombocytopenia may occur in 
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patients with type 2B. The bleeding time(BT) is usually prolonged, but may be 
normal in patients with mild forms of VWD especially when platelet VWF 
content is normal. The prothrombintime (PT) is normal whereas the 
Partialthromboplastintime(PTT) may be prolonged to a variable degree, 
depending on the plasma FVIII levels. 
Identification of the type 
VWF antigen (VWF: Ag) is unmeasurable in type 3VWD, whereas it may be 
low in type 1 and low or normal in type 2 VWD. 
The assay for ristocetin cofactor activity (VWF:RCo) explores the interaction 
of VWF with the platelet GpIb/IX/V complex and is still the standard method 
for measuring VWF activity. It is based on the property of the antibiotic 
ristocetin to agglutinate formalin-fixed normal platelets in the presence of 
VWF. In patients with a normal VWF structure (type 1 VWD), values of VWF: 
RCo are similar to those of VWF:Ag. Factor VIII coagulant activity (FVIII:C) 
plasma levels are very low (1–5%) in patients with type 3VWD. In patients with 
type 1 or type 2 VWD, 
FVIII:C may be decreased to a variable extent but sometimes is normal. 
The multimeric pattern of VWF can be analyzed by agarose gel electrophoresis. 
Low-resolution agarose gels distinguish VWF multimers, which are 
conventionally indicated as high, intermediate and low molecular weight. In 
type 1 VWD all multimers are present, whereas in type 2A and 2B high and 
intermediate or high molecular weight multimers, respectively, are missing. 
Characterization of the subtype 
For a correct diagnosis of patients with sVWD and their correct treatment, other 
assays are necessary to define specific subtypes. 
Ristocetin-induced platelet agglutination (RIPA) 
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is measured by mixing increasing concentrations of ristocetin and patient 
platelet-rich plasma (PRP)in the aggregometer. Results are expressed as the 
concentration of ristocetin (mg/mL) able to induce30% of agglutination. Most 
VWD types and subtypes are characterized by hyporesponsiveness toristocetin, 
at variance with type 2B, which is characterized by hyper-responsiveness to 
ristocetin, because of a higher than normal affinity of VWF for platelet 
GpIb/IX/V complex. 
VWF multimeric analysis with high-resolution agarose gels can allow better 
identification of type1 and 2 VWD subtypes. 
Platelet VWF has an important role in primary hemostasis, because it can be 
released from alphagranules directly at the site of vascular injury. On the basis 
of its measurement, type 1 VWD may be classified in three subtypes: 
? Type 1 “platelet normal”: with a normal content of functionally normal 
VWF. 
? Type 1 “platelet low”: with low concentrations of functionally normal VWF. 
? Type 1 “platelet discordant”: containing dysfunctional VWF in platelets. 
Factor VIII binding assay measures the affinity of VWF for FVIII. This assay 
allows type 2N VWD to be distinguished from mild to moderate hemophilia A. 
In general, a proportionate reduction of both VWF:Ag and VWF:RCo with 
RCo: Ag ratio 0.7suggests diagnosis of type 1. The ratio between FVIII and 
VWF:Ag is always ≥1 and the severity of type 1 VWD phenotype can usually 
be evaluated 
by performing platelet VWF measurements. If the VWF:RCo : Ag ratio is  0.7 
a type 2 VWD might be present. According to the RIPA method, type 2B VWD 
can be diagnosed in the case of an enhanced RIPA(0.8 mg/mL), while types 
2A and 2M are characterized by reduced RIPA (1.2 mg/mL). Multimeric 
analysis in plasma is necessary to distinguish between type 2A VWD (lack of 
the largest and intermediate multimers) and type 2M VWD(all the multimers 
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present as in normal plasma).Type 2N VWD can be suspected in case of 
discrepant values between FVIII and VWF:Ag (ratio0.7) and diagnosis should 
be confirmed by a specific test of VWF–FVIII binding capacity(VWF–FVIIIB). 
Additional tests used in VWD diagnosis include the closure time (CT) and 
assays of VWF activity based on binding to collagen (VWF:CB). The 
evaluation of CT with PFA-100® (Platelet Function Analyzer) allows rapid and 
simple determination of VWF-dependent platelet function at high shear stress. 
This system was demonstrated to be sensitive and reproducible for the screening 
of VWD, even though the CT is normal in type 2N VWD. However, its utility 
in the clinical setting remains to be demonstrated. Assays for VWF:CB are also 
available and the ratio of VWF:CB to VWF:Ag levels appears to be useful for 
distinguishing between type 1 and 2VWD. These relatively new assays have not 
been properly standardized yet and are not officially recommended by the 
Scientific Standardization Committee of the International Society of 
Thrombosis and Hemostasis. A new ELISA test exploiting the interaction of 
VWF with plate-immobilized GpIb in the presence of ristocetin seems to be 
very promising in replacing VWF:RCo; however, its validation remains still to 
be fully ascertained (17). 
Treatments and drugs: 
Even though von Willebrand disease is a lifelong condition with no cure, the 
doctor can treat it effectively. Treatment may vary, depending on the type and 
severity of the disorder, as well as the response to previous therapy and other 
medications. The most commonly used treatments for von Willebrand disease 
include:  
Desmopressin (DDAVP) 
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This medication is administered by injection into a vein or, more commonly, 
through a nasal spray called Stimate. It is a synthetic hormone, similar to the 
natural hormone vasopressin that controls bleeding by stimulating the body to 
release more von Willebrand factor already stored in the lining of blood vessels-
thereby enhancing factor VIII levels. DDAVP is usually effective in people with 
type 1 and some subtypes of type 2 disease. Many doctors consider it the first 
treatment to use in the management of von Willebrand disease. Some women 
use the nasal spray at the beginning of their menstrual periods to control 
excessive bleeding or before a minor surgical procedure. 
Replacement therapies 
These consist of infusions of prepared doses of concentrated blood clotting 
factors containing von Willebrand factor and factor VIII. They can be useful in 
all disease types 
Contraceptives 
These can be useful for controlling heavy bleeding during the menstrual 
periods. The estrogen hormones present in birth control pills can boost levels of 
von Willebrand factor and factor VIII activity. Another option is the placement 
in the uterus of a progesterone-containing contraceptive device. 
Antifibrinolytic or clot-stabilizing medications 
These medications, such as aminocaproic acid (Amicar) and tranexamic acid 
(Cyklokapron), can slow down the breakdown of clot putting a stop to bleeding.  
Fibrin sealants 
These substances, applied like a glue using syringes, are placed directly on a cut 
to curtail bleeding (16).  
Acquired forms of von Willebrand disease can be observed in the following 
conditions:  
o Wilms tumor  
o Congenital heart disease  
o Systemic lupus erythematosus 
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o Angiodysplasia 
o Seizure disorders treated with valproic acid  
o Hypothyroidism(16) 
 
Inhibitors 
 
Inhibitors are antibodies that neutralize coagulation factors. They are immune 
globulins, usually IgG, arising in congenitally deficient individuals as a result of 
administration of missing factors. Inhibitors are most common in patients with 
severe disease although they can occur in mild cases. The most common 
acquired inhibitors are those directed against factor VIII but antibodies against 
other Factors can occur e.g.: VWF and FIX. Approximately 25% of patients 
with severe Haemophilia A develop inhibitors after initial treatment with factor 
VIII Inhibitors concentrates. Approximately half of these appear transient and 
disappear with continued therapy with factor VIII. Therefore the diagnosis of an 
inhibitor, irrespective of titre, requires active monitoring and treatment to 
determine whether the inhibitor progresses to a high titre inhibitor or it is 
transient. The incidence of inhibitors in those with severe Haemophilia B is 
much less common (4%) but requires more careful individual management in 
aheamophilia treatment centre (HTC).Anaphylaxis can occur and is an 
additional complication(18) 
The risk of formation of an inhibitor is influenced by the type of mutation in the 
factor VIII gene. Large deletions, inversions and crossing over, and nonsense 
mutations are associated with the highest risk, probably because the recipient’s 
immune system recognizes the normal factor VIII replacement protein as a 
foreign molecule. The type of mutation also is associated with the severity of 
haemophiliaA. Thus, the association between the type of mutation and the 
development of inhibitors may be confounded by variables related to the 
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severity of illness, such as age at the first infusion of therapy or the cumulative 
number of days of replacement therapy(19) 
The early diagnosis of factor VIII inhibitors is essential. While the presence of 
an inhibitor can be suspected on clinical ground when the patient does not 
respond to conventional dose of factor VIII, laboratory diagnosis is required for 
confirmation.  
Inhibitor quantification is done by Bethesda assay and expressed in Bethesda 
unit (BU).An inhibitor is defined as low titre<5BU and high titre>5BU.Most of 
the high titre patients are high responding or presents anamnestic response. 
A low responding antibody remains at a low or moderate level, whereas in high 
responders, treatment with factors elicits a sharp anamnestic rise after 5 - 8 
days. Low responders can be treated by high dose of factorconcentrate while 
high responders are refractory to replacement therapy and therefore alternative 
therapies have been developed .Bypassing agents may be used to treat acute 
haemorrhage, the most common available bypassing agents are human 
recombinant FVIIa or plasma derived concentrates that contain activated 
coagulation factors such as FEIBA and Autoplex. Immune tolerance regimens 
can be used to eradicate high titre antibodies. The diagnosis of an inhibitor 
should be conducted using Bethesda criteria. After initial diagnosis of a low 
titre inhibitor in a patient with Haemophilia A, routine doses of factor VIII may 
be as much as doubled and the clinical response and inhibitor titre monitored. 
Subsequent poor clinical response or rising titre levels indicate a non-transient 
inhibitor. The diagnosis of a high titre inhibitor which does not respond to factor 
VIII should be treated with an alternative product (18). 
There is an incidence of inhibitors in those with mild Haemophilia A following 
treatment with factor VIII concentrates and the guidelines will also apply to 
those patients. DDAVP is occasionally used in mild to moderate haemophilia 
but is often ineffective. 
26 
The management of patients with Haemophilia A and inhibitors is complex and 
must be managed by a Haemophilia Treatment Centre (HTC). Major issues with 
treatment are firstly, the control of acute haemorrhage and secondly the 
eradication of the inhibitor (tolerisation)(20). 
Control of haemorrhage 
 Products Available 
? Factor VIII, either recombinant or plasma-derived 
? Recombinant factor VIIa 
? Activated prothrombin complex concentrate (eg FEIBA) 
? Prothrombin complex concentrate (egprothrombinex-HT) 
? Antifibrinolytics (egtranexamic acid) 
Note: Porcine factor VIII is no longer being manufactured. 
 
Factor VIII 
In the case of life threatening haemorrhage infusion of factor VIII in large doses 
can be used to swamp the inhibitor. This therapy is mostly used in patients with 
low responding inhibitors (inhibitor titre is <5 BU/mL after infusion of factor 
VIII). In patients who are high responders, this treatment may be effective 
provided the inhibitor level is less than 5 BU/mL. Factor levels should be 
observed to assess and monitor response. Anamnesis can occur 5-7 days after 
therapy and make factor VIII ineffective. Recombinant and plasma-derived 
factor VIII are available(21). 
Recombinant Factor VIIa 
This product has been widely used and has proved to be highly effective in the 
management of spontaneous bleeding episodes which are life threatening. 
Evidence in the literature suggests that it is effective in79-92% of such 
episodes. In addition, there is evidence that it is effective in over 90% of cases 
of surgery. 
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Recombinant factor VIIa is infused as a bolus. Continuous infusion of 
recombinant factor VIIa may reduce the quantity and cost of treatment but 
evidence is conflicting. A recent study suggests continuous infusion 
of50µg/kg/hr is effective in surgery. Antifibrinolytics are administered 
concurrently. The standard adult dose of recombinant factor VIIa is 90 µg/kg. 
However in children the mean half life is substantially reduced to 1.32 hours 
and thus higher doses of up to 200-250 µg/kg may be required.. There is 
widespread evidence that recombinant factor VIIa is effective for treatment of 
all haemorrhage in patients with high responding factor VIII inhibitors(20).  
Activated Prothrombin Complex Concentrates (APCCs) 
(E.g.FEIBA VH) 
Activated prothrombin complex concentrate, such as FEIBA VH, is effective in 
the treatment of 90% of bleeding episodes, and has been effective in the 
management of bleeding during major surgery. An effective dose is 60-
100units/kg twice per day. The maximum daily dose of FEIBA is 
200units/kg/day. 
Antifibrinolytic agents, such as tranexamic acid, should not be administered 
concurrently with FEIBA. It should be noted that FEIBA contains small 
amounts of factor VIII and therefore may cause elevation of inhibitor titres in 
some patients. There is a reported high incidence of thrombosis associated with 
their use; and it is not possible to measure their activity in a standardized way. 
Nevertheless, these products remain an option for treatment for complex cases 
in which alternative methods have proved ineffective. 
In patients who are having frequent bleeds, a trial of FEIBA as prophylaxis 
should be considered. The suggested dose is 75-100 units/kg three times a week. 
Prothrombinex-HT 
Despite general scepticism about the effectiveness of prothrombinex-HT in the 
management of joint haemorrhage, some patients report benefit and continue to 
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be treated with this product. There are concerns about the incidence of 
thrombosis when using repeated high doses, particularly in the presence of liver 
disease and when used in combination with antifibrinolytics. There is no 
evidence of efficacy in serious haemorrhages in surgery. 
Antifibrinolytic therapy 
The recommended dose of tranexamic acid is 80-100 mg/kg/day, with a 
standard dose being 1g, 8hr given orally (recommended paediatric dose is 
35mg/kg/8hr).  
Plasmapheresis / Immunoadsorption 
Plasmapheresis can be used to reduce inhibitor titres to allow effective therapy 
with factor VIII. There is as yet little information on the use of 
immunosuppression in patients with factor VIII inhibitors but some 
experimental protocols are being proposed. Immunosuppression has been 
associated with side effects including delayed wound healing and increased 
susceptibility to infection. Rituximab (anti CD 20monoclonal antibody) therapy 
may be considered as an adjunct therapy to reduce inhibitor titres. 
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Tolerisation: 
Immune tolerance induction is defined as eradication of an inhibitor by high 
dose antigen exposure with or without immune modulation therapy. Tolerisation 
is an active procedure that may involve development of antibodies against IgG 
factor VIII antibodies. Better results  occurs in those patients with a lower age at 
the start of ITI; shorter elapsed time of inhibitor presence before ITI; lower 
maximum pre-treatment inhibitor titres and treatment with higher doses of 
factor VIII(22). 
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Justification 
 
The development of inhibitors remains one of the most serious complications of 
replacement therapy in haemophiliaA patients. Patients with inhibitors need 
higher doses of factors or bypassing agents which is coasty and usually not 
available. This problem is under estimated and needs further work up to detect 
the true incidence and the risk factors and their effect on management.  
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Objectives 
 
Major: 
• To determine the prevalence of inhibitors in patients with haemophilia 
A. 
• To correlate the severity of illness with inhibitors level. 
Minor: 
• To measure FVIII level in patient with haemophilia A. 
•  To measure FVIII inhibitors in patients with haemophiliaA. 
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Material and Methods 
Study design: 
Cross sectional prospective study. 
Study area: 
Khartoum teaching hospital in haemophilia clinic in the period (January- May) 
2010. 
Study population: 
Inclusion criteria 
• All patients attending haemophilia clinic and previously diagnosed as 
hemophilia A and who accepted to participate in the study. 
• All ages will be included. 
• All severities (mild, moderate and severe). 
Exclusion criteria 
Patients who refuse to participate. 
Ethical consideration: 
 
Purpose of the study will be explained to the patients, written consent will be 
filled with patients. All patients will be informed about the results of their 
investigations to help the treating doctors in their management. 
Sample size 
80 patients. 
 
33 
 
Methodology 
 
Quantitative Measurement of factor VIII Inhibitors: 
Factor VIII inhibitors are usually time dependent .Thus if factor VIII is added to 
plasma containing an inhibitor and the mixture is incubated, factor VIII will be 
progressively neutralized .If the amount of factor VIII added and the duration of 
incubation are standardized, the strength of the inhibitor may be measured in 
units according to how much of the added factor VIII is destroyed(18).   
Inhibitors quantification will be done by Bethesda assay and expressed in 
Bethesda unit (BU). 
 In the Bethesda assay BU is defined as the amount of inhibitors that will 
neutralize 50% of 1 unit of FVIII content in normal plasma after 2 hours of 
incubation at c. 
Dilutions of the test plasma are incubated with an equal volume of the normal 
pooled plasma at c. The normal plasma pool is taken to represent one unit of 
factor VIII. Dilutions of the control normal plasma containing no inhibitors are 
treated in the same way, and equal volume of normal plasma mixed with buffer 
is taken to represent 100% value(18). 
At the end the residual factor VIII is assayed and inhibitors strength is 
calculated from the standard graph of residual factor VIII activity versus 
inhibitor unit. 
Reagents: 
1. Platelets poor plasma (ppp) from the patient .Blood was collected in 
containers with trisodium citrate anticoagulant  (9 volumes of blood to 
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1volume of trisodium citrate) , and then hard centrifugation at 3000g for 15 
minute  was done to collect ppp leaving the red cells and the buffy coat. 
2. Glyoxaline buffer.  
3.  APTT reagent. 
4. Factor VIII deficient plasma. 
5. Standard plasma (normal plasma pool). 
Method: 
Pipette into each of a series of plastic tubes 0.2ml of normal pool plasma .Add 
0.2ml of glyoxaline buffer to the first tube (this tube serves as 100% value); add 
0.2ml 0f test plasma dilutions in glyoxaline buffer to each of the other tubes 
,arrange of dilutions should be set up ranging from undiluted plasma to 1 in 50 
dilution.  
Cap, mix, and incubate all the tubes for 2 hours at c. Then perform factor 
VIII assay in all incubation mixtures. One stage assay of factor VIII based on 
APTT is done as follow: 
Serial dilutions of test and standard plasma in buffered saline in plastic tubes 
was made (1 in 5, 10,, 20, 40).Add to each dilution factor VIII deficient plasma 
and perform APTTs according to the laboratory protocol .The clotting time 
against factor VIII concentration is plotted on semi log paper and the 
concentration was read .It is important to obtain straight and parallel line if the 
result is to be accurate. The reasons for non-parallelism are technical errors, 
activation of plasma by poor collection, low concentration of factor VIII and 
presence of an inhibitor. 
Calculation of the Results and interpretation: 
The dilution of test plasma that give the residual factor VIII percentage nearest 
to 50% is chosen for calculating the strength of inhibitor .If the residual factor 
VIII activity is between 80%and 100% the plasma sample does not contain an 
inhibitor .If the residual activity is less than 60% the plasma unequivocally 
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contain an inhibitor .Values between 60% and 80% are borderline and 
additional sample is needed before the diagnosis can be established(18). 
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Results 
 
Table 1 shows age distribution of the study group. Twenty three (28.8%) were 
below the age of fifteen, forty three (53.8%) were between (15-30) and fourteen 
(17.5%) were above thirty.  
Table 2 shows distribution of severity among the study group.Twenty three 
Patients (28.7%) were with mild disease, thirty three (41.3%) of moderate 
disease and twenty four (30%) of severe disease 
Table 3 and figure 1 show the prevalence of inhibitors among the study group. 
Seventeen patients (21.3%) were found to have inhibitors. 
Table 4 and figure 2 show the distribution of level of inhibitors among the 
study group.Fifteen patients of low titre inhibitors (88.2%) and two of high titre 
(11.8%). 
Table 5 and figure 3 shows the number of visits to haemophilia clinic among 
the study group. Twenty eight patients (35%) have an average of visits  per year 
of less than 12,thirty two (40%) have an average of (12-24) visits per year and 
twenty patient (25%) visit the clinic more than 24 visit per year.  
Table 6 shows severity versus number of visits per year. Those with mild 
disease 5 out of 23 (21.73%) have a number of visits of less than 12, 13 out of 
23(56.5%) have a number of visits between 12-24 and 5 of 23 (21.73%) have 
more than 24 visits per year. Those with moderate disease 14 out of 33(42.4%) 
have number of visits less than 12, 9 out of 33(27.3%) have a number of visits 
between 12-24 and 10 out of 33 (30.3%) have more than 24 visits. Those with 
severe disease 9 out of 24(37.5%) have a number of visits less than 12, 10 out of 
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24 (41.7%) have a number of visits between 12-24 and 5 out of 24(20.8%) have 
more than 24 visits per year (P value>0.005). This correlation is in significant. 
Table 7 shows the number of vials (1 vial= 500 unit) of factor VIII taken in the 
last month. 34 patients (42.5%) have an average of vials (0-1), 30 patients 
(37.5%) have an average of (2-5), 14 patient (17.5%) have an average of (6-10) 
and 2 patients (2.5%) have an average of (10-30). 
Table 8 shows the severity versus inhibitors .Patients with no inhibitors 17 out 
of 62(27.4%) are of mild disease, 29 out of 62 (46.8%) of moderate disease and 
16 out of 62 (25.8%) of severe disease. Patients with low titre inhibitors 5 of 15 
(33.3%) of mild disease and 3 of 15(20%) of moderate disease and 7 of 15 
(46.7%) of sever disease. Patients of high titre inhibitors 1of 2 (50%) are of 
mild disease and 1 of 2(50%) of sever disease. (P value >0.005)This correlation 
is insignificant. 
Table 9 show the inhibitors versus number of vials taken in the last month. 
Patients with the least number of vials (0-1) are 34 .28 of them (82.4%) are with 
no inhibitors, 6 0f them (17.6%) of low titre inhibitors and no one with high 
titre Those who have a number of visits between (2-5) are 29 patients, 24 of 
them (79.3%) with no inhibitors, 6 of them (20.7%) are of low titre inhibitors 
and no one with high titre. Those with number of visits between (6-10) are 14, 
10 of them (71.4%) are with no inhibitors, 3 of them (21.4%) with low titre and 
one patient (7.2%) with high titre .Patients with number of vials between (10-
30) are two patients one of them with high titre inhibitors (50%) and one with 
no inhibitors (50%).(P value < 0.005) this correlation is significant. 
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Table 1:  Age distribution of the study group 
 
Age group 
(Yrs) 
Frequency Percentage 
(%) 
< 15 23 28.8 
15-30 yrs 43 53.8 
>30 yrs 14 17.5 
Total 80 100.0 
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Table 2: Distribution of severity among the study group 
 
Severity Frequency Percentage 
(%) 
Mild 23 28.7 
Moderate 33 41.3 
Severe 24 30 
Total 80 100.0 
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Table 3:  prevalence of inhibitors in the study group 
 
Prevalence of 
inhibitors 
Frequency Percentage 
(%) 
Positive 17 21.3 
Negative 63 78.8 
Total 80 100.0 
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Table 4: Distribution of level of inhibitor among the study 
group 
 
Inhibitors  Frequency Percentage 
(%) 
Low titre 15 88.2 
High titre 2 11.8 
Total 17 100.0 
 
Low titre (<5BU) 
High titre (> 5 BU) 
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Table 5:  Distribution of number of visits per year. 
 
No. of visits Frequency Percentage 
(%) 
< 12 28 35.0 
12-24 32 40.0 
> 24 20 25.0 
Total 80 100.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43 
Table 6: Severity versus number of visits per year 
 
 
 
 Number of visits per year 
 < 12 12-24 > 24 
Severity No. % No % No % 
Mild 5 21.73 13 56.5 5 21.73 
Moderate 14 42.4 9 27.3 10 30.3 
Severe 9 37.5 10 41.7 5 20.8 
Total 28  32  20  
 
P value = > 0.005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
Table 7: Number of vials taken in the last month. 
 
 
No. of vials Frequency Percentage 
(%) 
0-1 34 42.5 
2-5 30 37.5 
6-10 14 17.5 
10 – 30 2 2.5 
Total 80 100.0 
 
1 vial =500 unit 
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Table 8: Severity versus inhibitors 
 
 
Severity 
 
Inhibitors 
 No Low titre High titre 
 No. % No % No % 
Mild 17 27.4 5 33.3 1 50.0 
Moderate 29 46.8 3 20.0 0 0.0 
Severe 16 25.8 7 46.7 1 50.0 
Total 62 100.0 15 100.0 2 100.0 
 
P value > 0.005 
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Table 9: Inhibitors versus number of vials taken in the last 
month. 
 
 
Inhibitors 
 
No. of vials taken in the last month 
 0-1 2-5 6-10 10-30 
 No. % No. % No % No % 
No 28 82.4 24 79.3 10 71.4 1 50 
Low titre 6 17.6 6 20.7 3 21.4 0 0.0 
High titre 0 0.0 0.0 0.0 1 7.2 1 50 
Total 34 100.0 29 100.0 14 100.0 2 100.0 
 
1 vial=500 unit 
           P value    <0 .005  
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4.1 Discussion 
 
The development of inhibitor remains one of the most serious complications of replacement 
therapy in inherited coagulation disorders. 
This study was designed to assess the prevalence of inhibitors among patients with 
haemophilia A presenting to haemophilia clinic in Khartoum teaching hospital in the period 
from January to May 2010. 
Inhibitor quantification was done by Bethesda assay and expressed in Bethesda unit (BU).  
BU is defined as the amount of inhibitors that will neutralize 50% of 1 unit of FVIII content 
in normal plasma after 2 hours of incubation at C. 
An inhibitor is defined as low titre<5BU and high titre>5BU. A low responding antibody 
remains at a low or moderate level, whereas in high responders ,treatment with factors elicits 
a sharp anamnestic rise after 5 - 8 days .Low  responders can be treated by high dose of factor 
concentrate while high responders are refractory to replacement  therapy and therefore 
alternative therapies have been developed .Bypassing agents may be used to treat acute 
hemorrhage ,the most common available bypassing agents are human recombinant  FVIIa or 
plasma derived concentrates that contain activated coagulation factors such as FEIBA and 
Autoplex. Immune tolerance regimens can be used to eradicate high titre antibodies. 
Inhibitor should be looked for every six months in haemophilics on regular replacement 
therapy which is not done in Sudan due to cost. Inhibitor is only looked for after clinical 
suspicion of its presence due to suboptimal response to treatment. 
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Eighty patients with haemophilia A were included in this study. As haemophilia 
A is an X- linked disease all were males. Their ages ranged between 3-60 years. 
Twenty three Patients (28.7%) were with mild disease, thirty three(41.3%) of 
moderate disease and twenty four(30%) of severe disease. 
When they were investigated for inhibitors seventeen patients (21.3%) were 
found to have an inhibitor. Fifteen patients of low titre inhibitors (18.8%) and 
two of high titre (2.5%).This result is comparable to the prevalence of inhibitors 
of (15-25%) in haemophilia A as mentioned in the literature . 
Inhibitors were detected in 6 of 23 of patient with mild disease (26%) and 3 of 
33 (9%) patients with moderate disease and 8 of 24(33.3%) of severely affected 
patients.(p>o.o5).This correlation of inhibitors with the severity of the disease is 
significant for severely affected patients. Regarding those with moderate and 
mild disease this correlation was insignificant as inhibitors is expected to be 
higher in those with moderate disease. An explanation is that our patients are 
treated on demand. There is no home therapy and patient have to come to 
haemophilia centre each time they have a bleed. The development of inhibitors 
is affected by the rate of exposure to replacement therapy. Frequency of 
exposure will be determined not only frequency of bleeding but also the 
geographical distance to haemophilia centre and affordability of transport. It is 
also determined by the availability of factor concentrate as it is not always 
available and many patients refuse to receive plasma replacement. 
Thirty two patients (40%) had an average of 24 visits per year with bleeding 
episodes and received treatment with factor VIII concentrate, fresh frozen 
plasma or cryoprecipitate, and twenty (25%) have more frequent visits>24 . 
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Those with high titre inhibitors had more frequent visits to haemophilia clinic 
and received more units of factor VIII during the last month. The two patients 
with high titre inhibitors receive an average of 30 vials of (500) IU during the 
last month which is a very large amount in comparison with those without 
inhibitors. Again this was significant as patient with inhibitors require more 
amount of replacement therapy because it will be partially or completely 
neutralized by the antibodies(p value<0.005). 
A previous study done in turkey by Hale Oren Yapark and, Dokuz Eylu, reveals 
that in 58 haemophilia A patients the prevalence of inhibitors was found to be 
27% by Bethesda assay method. 
Inhibitors were not detected in any of 14 patients with mild disease, present in9 
of 27 (33%) patients with moderate disease and 7 of 17(41) patients with severe 
disease. During follow up for one year the inhibitors were transient in 10 of 16 
(17%) and the prevalence of inhibitors 10% at the end of the study (23). Follow 
up the patients with inhibitors is important as many inhibitors in patient with 
mild disease are transient. This was not done in our study. 
Another study was done in Iran by R. Sharifian, M. Hoseini, R. Safai, Gh. 
Tugeh, A.H. Ehsani, M. Lak and M. Jazeb. 
 1280 hemophilia A patients (age range 9 months-84 years) were evaluated. All 
patients received several blood products such as fresh frozen plasma 
(FFP),cryoprecipitate, factor VIII. 635 of 1280 patients (49.6%), 277 patients 
(21.6%) and 368 patients(28.8%) had severe, moderate and mild disease, 
respectively. 184 of 1280 patients (14.4%) developed inhibitor. The prevalence 
of inhibitor for severe, moderate and mild in hemophilia A patients was 22.8%, 
9.4%, 3.5% respectively. 41 patients (22.2%) were high responder and 143 
patients (77.8%)   were low responder (24). 
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In comparison to our study the prevalence of inhibitors was higher in patient 
with moderate disease than mild disease which is not found in our study. 
Factors that appear to affect inhibitor development include the severity of 
hemophilia, age, genetics, and, possibly, the type of replacement therapy 
administered. Recent studies raise the concern that recombinant factor therapies 
may be associated with more rapid development and higher levels of inhibitors 
in previously untreated patients. However, results of different studies are often 
difficult to compare owing to differences in methodology and populations 
studied. Further studies standardized in design and methods are clearly 
needed(25). 
A comparative study of measurement of FVIII inhibitors using ELISA and the 
Bethesda assay done in Korea by KIM SY ,KANG SY, LEE WI ,reveals 
thatFactor VIII inhibitors are produced during or after coagulation factor VIII 
(FVIII) therapy in hemophilia A patients. These inhibitors are usually detected 
by a modified Bethesda assay or an enzyme-linked immunosorbent assay 
(ELISA). In this study, they used the Bethesda assay to determine the incidence 
of FVIII inhibitors in 75 fresh plasma samples obtained from 50 hemophilia A 
patients, and then used ELISA and the Bethesda assay to determine the titres of 
these inhibitors after the samples had been frozen and thawed. The samples 
from the screening Bethesda assay were centrifuged and stored at -70 degrees C 
in accordance with the assay guidelines. Subsequently, these samples were 
thawed and analyzed using ELISA and the Bethesda assay. The incidence of 
inhibitors in hemophilia A patients was 20.0%. Among the 35 inhibitor-positive 
samples identified in the screening Bethesda assay, 16 were positive in ELISA 
while only 4 were positive in the repeated Bethesda assay. In this study, the 
ELISA technique showed a higher sensitivity than the Bethesda assay in the 
detection of FVIII inhibitors in samples that were subjected to freezing and 
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thawing procedures; this was because the Bethesda assay could not identify the 
FVIII inhibitors that were degraded after freezing and thawing(26). 
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4.2Conclusion 
 
From this study we conclude that, prevalence of factor VIII inhibitors in patients with 
haemophiliaA attending haemophilia clinic in the period from January to May 2010 was 
21.3% (seventeen patients). Fifteen patients of low titre inhibitors (18.8%) and two of high 
titre (2.5%).This result was significant as the prevalence of inhibitors was 15-25% in 
haemophilia A as mentioned in the literature . Inhibitors are most common among severely 
diseased patients. Those with inhibitors had more frequent visits and receive more amount of 
factor VIII concentrate during the last month when compared with patients with no inhibitors. 
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4.3 Recommendations 
 
• Further in depth studies involving more number of patients is needed as developing of 
inhibitor is an ongoing process. 
• Annual screening for inhibitors for every hemophilic patient.  
• Follow up of patient with inhibitors is important as many of them are transient and 
disappear after time and others increase by replacement therapy 
• Measurement of inhibitors should be done regularly every six months for those who 
receive replacement therapy. 
• Risk factors for developing inhibitors need to be evaluated and studied including age of 
first exposure to replacement therapy and type and purity of factor VIII concentrate. 
• Genetic studies are recommended to identify those who are at increased risk for 
developing inhibitors 
• Automation for testing of inhibitors and using ELISA is needed to increase the sensitivity 
and specificity. 
 
  
 
 
 
 
 
 
 
 
54 
 
References 
 
1. A.VictorHoffbrand, Daniel Catovsky, Edward G.D.Tuddenham.  Postgraduate 
haematology text book, fifth edition .London: Blackwell: 2005.p 783-807. 
2. Hirsh J, Dalen JE, Anderson DR.Oral anticoagulant;mechanism of action,clinical 
effectiveness and optimal therapeutic range.1998.114;445-469.  
3. A.V.HoffbrandJ.E.Pettit and P.A.H.Moss .Essential haematology, fourth edition. London 
Blackwell: 2003 p 236-249. 
4. Leissinger CA.Prvention of bleeds in haemophilia patients with inhibitors: emerging data 
and clinical direction. Am j hematol 2004 p,77:187-193. 
5.  Brink us KM: A short history of haemophilia, with some comments on the word 
haemophilia, in handbook of haemophilia ,edited by KM brinkhous, HC Hemker,p3 
,1975.   
6. Fay PJ Reconstitution of human factor VIII from isolated subunits. Arch Biochem Biophys 
262:525, 1988. 
7. Roberts HR, Monroe DM, Oliver JA. Newer concepts of blood coagulation, Haemophilia 
4:331, 1998. 
8. Tuddenham EGD: FVIII in Molecular Basis of Thrombosis and haemostasis edited by 
High KA and Roberts HR .Marcel Dekker,p167 ,New York,1995.  
9. Lakich D, Antonarakis SE, Gitschier J: Inversions disrupting the factor VIII gene are a 
common cause of sever haemophilia A, Nat Genet 5:236,1993. 
10.Nichols WC,Amano K, Cacheris PM, Moderation of haemophilia A phenotype by the 
factor V R506Q mutation.Blood 88:1183, 1996. 
11.Cinotti S,Longo G ,Messori A, Reproducibility of one stage ,two stage and chromogenic 
assays of factor VIII activity: amulti-center study. Thrombo Res61(4):385,1991. 
12. Peake IR, Lillicarp DP, Boulyjenkov V,Report of a joint WHO/WFH meeting on control 
of haemophilia ,carrier detection and prenatal diagnosis. Blood Coagul Fibrinolysis 
4:313, 1993. 
55 
13. Souci JM, Robertson BH, Bell BP, Hepatitis A virus associated with clotting factor 
concentrate in the united states. Transfusion 38:573,1998. 
14.Eyster ME, Schaefer JH, Ragni MV,impact of liver disease and acquired 
immunodeficiency syndrome. Blood 79:2494, 1992. 
15.Biggs R, Doglas AS, Macfarlance RG, Daci JV, Pitney WR, Mersky C, Obrien JR. 
Christmas disease a condition previously mistaken for haemophilia (http.en .wikpedia 
.org/wiki/Haemophilia B ,lastly modified on 31/July/2010). 
16.John D Geil, MD, Associate Professor of Pediatrics, Division of Hematology/Oncology, 
University of Kentucky College of Medicine; Consulting Staff, Department of Pediatric 
Hematology/Oncology. (http://emedicine.medscape.com/article/959825, over view. 
17.Denise O Shaughnesy, Michael Maris, DavidLillicarp .Practical haemostasis and 
thrombosis .London Blackwell:2005.p 51-62. 
18. S.Mitchell Lewis, Babara J.Bain, Imelda Bates. Daci and Lewis practical 
haematology,UK, tenth edition 2006.p380-415. 
19.Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII 
concentrate on the incidence of factor VIII inhibitors in previously untreated patients 
with severe hemophilia A. Blood 2006. 
20.Liod-Jones M .Control of bleeding in patients with haemophilia A  
with inhibitors 2003 
21. Di Michele DM. Inhibitor development in haemophilia;an orphan disease in need of 
attention 2007.138;305-315. 
22.Paisly S, Wigh J Currie E ,Kniht C.The management of inhibitors in haemophilia A 
.Introduction and systemic review of current practice .Haemophilia  2003;9(4);405-17. 
23. Hale Oren Yapark, ,Dokuz Eylul university ,Faculty of medicine ,department of 
paediatric haematology 1995 
24. R. Sharifian, M. Hoseini, R. Safai, Gh. Tugeh, A.H.Ehsani, M. Lak and M. Jazeb 
.Department of Hematology, Imam khomeini Hospital, School of Medicine, Tehran 
university of Medical sciences,Tehran, Iran 
56 
25.   Louis Aledort, Professor of Medicine, Dean for Faculty and Medical Affairs, Mount 
Sinai Medical Center, I Gustave Levy Place, Box 1006, New York, June 2004(www 
inter science wiley.com/journal/112700668/abstract) 
26.KIM SY ,KANG SY, LEE WI, department of laboratory medicine Kyung heel ,University 
school of medicine Seoul korea , Comparative measurement of FVIII inhibitors in 
haemophilia A patients using ELISA and Bethesda assay.2010. 
 
 
57 
  Serial number                                    
  
University of Khartoum 
                           Medical Postgraduate Studies Board 
                                     Department of pathology 
                                             Questionnaire  
Name:……………………………………………………………………………. 
Age   years 
Sex:                                    Male              Female                            
Telephone……………… 
Residence:………………………………………………………………………  
Diagnosis:……………………………………………………………………….    
Duration of disease   years 
Number of hospital visits per month                  per year  
Present complaint:…………………………………………………………...... 
Types of medications: Factor             NovoVII           Others 
Number of factor units taken in the last month:   units 
Investigation: 
Factor level    
                                                     
  Inhibitor quantification by Bethesda assay                   BU 
  
Date:……………………                        Signature:………………………….  
